Mehdi Shahidi

Mehdi is a drug development expert and a R&D leader with broad experience from translational through clinical development, filing, registration and commercialisation.  He is an advisor to the Medicxi investment team. 

Prior to joining Medicxi, he was SVP and Chief Medical Officer at Boehringer Ingelheim (BI), leading clinical development, medical affairs, regulatory affairs, pharmacovigilance, biostatistics and quality across the complete portfolio and all phases. He oversaw the successful first in man transition of more than 30 NME's and the submission and regulatory approval of multiple compounds in different therapeutics areas. 

In his earlier years at BI, he led the clinical development of oncology programs from phase I to successful global filing and registration and assumed oversight of BI's oncology portfolio in his role as Global Head of Medicine, Oncology.

Mehdi studied Medicine in Tehran and completed his specialist training in Clinical Oncology at the Royal Marsden Hospital in London. He has many years of experience in patient care as a practicing oncologist and in academia as a senior clinical research fellow at the Institute of Cancer Research, London. He also held positions as Medical Director of Oncology at PRA International and Medical Expert, Oncology at Novartis UK.